6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …

Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed pts with CML-
CP (O'Brien et al, NEJM 2003). At 42-months of follow-up, 75% of the 553 pts randomized to …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …

IM has proven to be superior to IFN+ Ara-C for newly diagnosed pts with CML-CP (O'Brien et
al, NEJM, 2003). At 30-months of follow-up, 79% of pts randomized to IM remain on IM with …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

The International Randomized Study of Interferon and STI571 (IRIS) study prospectively
compared imatinib with interferon-alpha/low-dose cytarabine (IFN/LDAC) in 1,106 newly …

Purpose Long-term clinical outcome data have established imatinib 400 mg/d as standard
front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML) …

Background: IM 400 mg/d is the standard of care for pts with newly diagnosed CML-CP.
Previous reports suggest the rate of major molecular response (MMR), defined as BCR …

Imatinib at a dose of 400 mg daily is considered frontline treatment in chronic phase chronic
myeloid leukemia (CP‐CML). We conducted a systematic review and meta‐analysis of …

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase
chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International …